All In Biotech

Drug Trial Radar · NCT07318584

Cefotetan Therapy for Escherichia Coli Infections

Cefotetan Therapy for Escherichia Coli Infections: a Prospective Phase II Pilot Study

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Jun 26, 2026

Primary completion

Oct 2028

Study completion Apr 2029

Sponsor

Lead sponsor
Oregon Health and Science UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This pilot study will compare clinical outcomes among patients treated with cefotetan versus standard of care antibiotics for bacteremia caused by E. coli. It will also measure cefotetan minimum inhibitory concentration (MIC) distributions and cefotetan trough serum concentrations.

Conditions

  • E Coli Infection
  • ESBL Producing E.Coli

Interventions

  • CefotetanDrug

    Minimum 1 dose cefotetan within 24 hours of randomization. Creatinine clearance (CrCl) \>30 mL/minute: 2 g IV every 12 hours; CrCl 10-30 mL/minute: 2 g IV every 24 hours; CrCl \<10 mL/minute: 2 g IV every 48 hours

  • CarbapenemsDrug

    Preferred antibiotic for ESBL E. coli infections: ertapenem. Minimum 1 dose within 24 hours of randomization.

  • Beta Lactam AntibioticsDrug

    Beta lactam antibiotics for non-ESBL E. coli infections include preferred ceftriaxone or alternative cephalosporins (cefepime, ceftazidime), penicillins (piperacillin-tazobactam, ampicillin-sulbactam), and carbapenems (ertapenem, meropenem). Minimum 1 dose within 24 hours of randomization.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical successTime frame: From randomization through 30 days.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Oregon Health & Science University

    Portland, Oregon · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.